

# Key Information Document

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

You are about to purchase a product that is not simple and may be difficult to understand.

## Product

Product name	Autocallable Barrier Worst-of Phoenix Certificate Linked to a Basket of Ordinary Shares
Product identifier	ISIN: IT0006765017
PRIIP manufacturer	Marex Financial (www.marexfp.com) Call +44 (0)208-050-3561 for more information.
Competent authority of the PRIIP manufacturer	Authorised and regulated by the U.K. Financial Conduct Authority
Date and time of production	4 December 2025 7:09 Rome local time

## 1. What is this product?

**Type** English law governed equity-linked certificates / Return depends on the performance of the underlyings / No capital protection against market risk

**Term** The product has a fixed term and will be due on 25 August 2027, subject to an early redemption.

**Objectives** The product is designed to provide a return in the form of (1) fixed or conditional coupon payments and (2) a cash payment on termination of the product. The timing and amount of these payments will depend on the performance of the **underlyings**. If, at maturity, the **final reference price** of the **worst performing underlying** has fallen to or below its **barrier price**, the product may return less than the **product notional amount** or even zero.

(Terms that appear in **bold** in this section are described in more detail in the table(s) below.)

**Early termination following an autocall:** The product will terminate prior to the **maturity date** if, on any **autocall observation date**, the **reference price** of the **worst performing underlying** is above its **autocall barrier price**. On any such early termination, you will on the immediately following **autocall payment date** receive, in addition to any final coupon payment, a cash payment equal to the autocall payment of EUR 1,000.00. No coupon payments will be made on any date after such **autocall payment date**.

**Coupon:** On 27 September 2024 you will receive a coupon payment of EUR 155.00. This coupon payment is not linked to the performance of the **underlyings**. If the product has not terminated early, on each **coupon payment date** from and including 25 October 2024 you will receive a conditional coupon payment of EUR 3.34 together with any previously unpaid coupon payments if the **reference price** of the **worst performing underlying** is at or above its **coupon barrier price** on the immediately preceding **coupon observation date**. If this condition is not met, you will receive no coupon payment on such **coupon payment date**. The relevant dates are shown in the table(s) below.

Coupon observation dates	Coupon payment dates
-	27 September 2024
16 October 2024	25 October 2024
18 November 2024	27 November 2024
16 December 2024	30 December 2024
16 January 2025	28 January 2025
18 February 2025	27 February 2025
17 March 2025	26 March 2025
16 April 2025	29 April 2025
16 May 2025	28 May 2025
16 June 2025	26 June 2025
16 July 2025	25 July 2025
18 August 2025	27 August 2025
16 September 2025	25 September 2025
16 October 2025	27 October 2025
17 November 2025	26 November 2025
16 December 2025	30 December 2025
16 January 2026	28 January 2026
17 February 2026	26 February 2026
16 March 2026	25 March 2026
16 April 2026	27 April 2026
18 May 2026	28 May 2026
16 June 2026	26 June 2026
16 July 2026	27 July 2026
17 August 2026	26 August 2026
16 September 2026	25 September 2026
16 October 2026	27 October 2026
16 November 2026	25 November 2026
16 December 2026	29 December 2026
19 January 2027	28 January 2027
16 February 2027	25 February 2027
16 March 2027	25 March 2027
16 April 2027	27 April 2027
17 May 2027	26 May 2027
16 June 2027	28 June 2027
16 July 2027	27 July 2027
16 August 2027	Maturity date

**Termination on the maturity date:** If the product has not terminated early, on the **maturity date** you will receive:

1. if the **final reference price** of the **worst performing underlying** is above its **barrier price**, a cash payment equal to EUR 1,000.00; or

2. if the **final reference price** of the **worst performing underlying** is at or below its **barrier price**, a cash payment directly linked to the performance of the **worst performing underlying**. The cash payment will equal (i) the **product notional amount** multiplied by (ii) (A) the **final reference price** of the **worst performing underlying** divided by (B) its **strike price**.

Under the product terms, certain dates specified above and below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.

The product terms also provide that if certain exceptional events occur (1) adjustments may be made to the product and/or (2) the issuer may terminate the product early. These events are specified in the product terms and principally relate to the **underlyings**, the product and the issuer. The return (if any) you receive on such early termination is likely to be different from the scenarios described above and may be less than the amount you invested.

When purchasing this product during its lifetime, the purchase price may include accrued coupon on a pro rata basis.

You do not have any entitlement to a dividend from any of the **underlyings** and you have no right to any further entitlement resulting from any such **underlying** (e.g., voting rights).

<b>Underlyings</b>	Ordinary shares of Sanofi SA (SAN; ISIN: FR0000120578; Bloomberg: SAN FP Equity; RIC: SASYP.A), Eli Lilly & Company (LLY; ISIN: US5324571083; Bloomberg: LLY UN Equity; RIC: LLY.N) and Moderna Inc. (MRNA; ISIN: US60770K1079; Bloomberg: MRNA UW Equity; RIC: MRNA.OQ)	<b>Reference sources</b>	<ul style="list-style-type: none"> <li>• SAN: Euronext Paris</li> <li>• LLY: New York Stock Exchange</li> <li>• MRNA: NASDAQ GS</li> </ul>
<b>Underlying market</b>	Equity	<b>Final reference price</b>	The <b>reference price</b> on the <b>final valuation date</b>
<b>Product notional amount</b>	EUR 1,000.00	<b>Initial valuation date</b>	16 August 2024
<b>Product currency</b>	Euro (EUR)	<b>Final valuation date</b>	16 August 2027
<b>Underlying currencies</b>	<ul style="list-style-type: none"> <li>• SAN: EUR</li> <li>• LLY: U.S. Dollar (USD)</li> <li>• MRNA: USD</li> </ul>	<b>Maturity date / term</b>	25 August 2027
<b>Issue date</b>	21 August 2024	<b>Autocall observation dates</b>	The 16th calendar day of each month from May 2025 (inclusive) to the <b>final valuation date</b> (inclusive)
<b>Initial reference price</b>	<ul style="list-style-type: none"> <li>• SAN: EUR 98.57</li> <li>• LLY: USD 922.12</li> <li>• MRNA: USD 86.84</li> </ul>	<b>Autocall barrier price</b>	100.00% of the <b>initial reference price</b>
<b>Strike price</b>	100.00% of the <b>initial reference price</b>	<b>Autocall payment date</b>	The day falling 7 <b>business days</b> after the relevant <b>autocall observation date</b>
<b>Barrier price</b>	50.00% of the <b>initial reference price</b>	<b>Coupon barrier price</b>	50.00% of the <b>initial reference price</b>
<b>Reference price</b>	The closing price of an <b>underlying</b> as per the relevant <b>reference source</b>	<b>Worst performing underlying</b>	For a given date, the <b>underlying</b> with the worst performance between the <b>initial reference price</b> and the relevant <b>reference price</b>


## Intended retail client

The product is intended to be offered to retail investors who fulfil all of the criteria below:

- they have the ability to make an informed investment decision through sufficient knowledge and understanding of the product and its specific risks and rewards, either independently or through professional advice, and they may have experience of investing in and/or holding a number of similar products providing a similar market exposure;
- they seek income, expect the movement in the underlyings to perform in a way that generates a positive return. They have a medium investment horizon and understand that the product may terminate early;
- they are able to bear a total loss of their initial investment, consistent with the redemption profile of the product at maturity (market risk);
- they accept the risk that the issuer could fail to pay or perform its obligations under the product irrespective of the redemption profile of the product (credit risk);
- they are willing to accept a level of risk of 6 out of 7 to achieve potential returns, which reflects the second highest risk (as shown in the summary risk indicator below which takes into account both market risk and credit risk).

## 2. What are the risks and what could I get in return?

### Risk indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 6 out of 7, which is the second-highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are unlikely to impact our capacity to pay you.

Inflation erodes the purchasing value of cash over time and this may result in the decline in real terms of any capital reimbursed or interest you may be paid under the investment.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

For detailed information about all risks relating to the product please refer to the risk sections of the prospectus and any supplements thereto as specified in the section "7. Other relevant information" below.

## Performance scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The scenarios shown are illustrations based on results from the past and on certain assumptions. Markets could develop very differently in the future.

<b>Recommended holding period:</b>		<b>Until the product is called or matures</b>	
		This may be different in each scenario and is indicated in the table	
<b>Example investment:</b>		EUR 10,000	
<b>Scenarios</b>		<i>If you exit after 1 year</i>	<i>If you exit at call or maturity</i>
<b>Minimum</b>	There is no minimum guaranteed return. You could lose some or all of your investment.		
<b>Stress</b>	<b>What you might get back after costs</b>	EUR 746	EUR 681
(product ends after 1 year and 8 months)	Average return each year	-92.54%	-78.88%

<b>Unfavourable</b> (product ends after 1 year and 8 months)	<b>What you might get back after costs</b> Average return each year	EUR 2,863 -71.37%	EUR 1,857 -62.26%
<b>Moderate</b> (product ends after 1 year and 8 months)	<b>What you might get back after costs</b> Average return each year	EUR 7,339 -26.61%	EUR 5,816 -26.92%
<b>Favourable</b> (product ends after 1 year and 8 months)	<b>What you might get back after costs</b> Average return each year	EUR 18,717 87.17%	EUR 28,162 82.08%

The favourable, moderate, unfavourable and stress scenarios represent possible outcomes that have been calculated based on simulations using the past performance of the **underlyings** over a period of up to 5 years. In the case of an early redemption, it has been assumed that no reinvestment has occurred. The stress scenario shows what you might get back in extreme market circumstances. This product cannot be easily cashed in. If you exit the investment earlier than the recommended holding period, you may have to pay extra costs.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

### 3. What happens if Marex Financial is unable to pay out?

You are exposed to the risk that the issuer might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not covered by any deposit protection scheme.

### 4. What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

#### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different investment periods.

The duration of this product is uncertain as it may terminate at different times depending on how the market evolves. The amounts shown here consider two different scenarios (early call and maturity). In case you decide to exit before the product ends, exit costs may apply in addition to the amounts shown here.

We have assumed:

- EUR 10,000 is invested
- a performance of the product that is consistent with each holding period shown.

	<i>If the product is called at the first possible date, on 27 April 2026</i>	<i>If the product reaches maturity</i>
<b>Total costs</b>	EUR 105	EUR 105
<b>Annual cost impact*</b>	2.85%	0.45% each year

\*This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at maturity your average return per year is projected to be -26.45% before costs and -26.90% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

#### Composition of costs

	<b>One-off costs upon entry or exit</b>	<b>If you exit after 1 year</b>
<b>Entry costs</b>	1.05% of the amount you pay when entering this investment. These costs are already included in the price you pay.	EUR 105
<b>Exit costs</b>	0.93% of your investment before it is paid out to you. These costs are already included in the price you receive and are only incurred if you exit before maturity. If an early redemption occurs or if you hold the product until maturity, no exit costs will be incurred.	EUR 93

### 5. How long should I hold it and can I take money out early?

#### Recommended holding period: 1 year and 8 months

The product aims to provide you with the return described under "1. What is this product?" above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 25 August 2027 (maturity), although the product may terminate early.

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is exchange traded) or (2) off-exchange, where an offer for such product exists. Save as otherwise disclosed in exit costs (see section "4. What are the costs?" above), no fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

<b>Exchange listing</b>	EuroTLX	<b>Price quotation</b>	Units
<b>Smallest tradable unit</b>	1 unit		

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

### 6. How can I complain?

Any complaint regarding the conduct of the person advising on, or selling, the product can be submitted directly to that person.

Any complaint regarding the product or the conduct of the manufacturer of this product can be submitted in writing at the following address: Marex Financial, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom, by email to: [complaints@marexfp.com](mailto:complaints@marexfp.com) or at the following website: [www.marexfp.com](http://www.marexfp.com).

### 7. Other relevant information

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are published on [www.certificati.marex.com](http://www.certificati.marex.com), all in accordance with relevant legal requirements. These documents are also available free of charge from Marex Financial, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom. Call +44 (0)208-050-8636 for more information.